Comparative Pharmacology
Head-to-head clinical analysis: TERRAMYCIN versus VIBRA TABS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TERRAMYCIN versus VIBRA TABS.
TERRAMYCIN vs VIBRA-TABS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
Tetracycline antibiotic; inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
250-500 mg orally every 6 hours or 1-2 g intravenously every 12 hours. Maximum oral dose: 2 g/day.
100 mg orally twice daily on day 1, then 100 mg orally once daily
None Documented
None Documented
Terminal elimination half-life: 8-10 hours in normal renal function; prolonged to 20-40 hours in severe renal impairment (creatinine clearance <10 mL/min).
Terminal elimination half-life: 18-22 hours (single dose); increases to 24-48 hours in renal impairment. Mean half-life after multiple doses: 14-16 hours.
Renal (primarily glomerular filtration, 20-60% unchanged in urine), biliary/fecal (10-30% via bile into feces).
Renal (40% as unchanged drug via glomerular filtration), biliary/fecal (20-30%, including enterohepatic circulation).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic